Curesponse's technology was developed by Dr. Ravid Straussman and Dr. Nancy Gavert at the Weizmann Institute of Science. Motivated by a desire to improve cancer research and drug diagnostics, the pair engineered the platform after years of careful and dedicated research. Their work is one of the leading technologies developed at Weizmann, which is one of the world's top multidisciplinary basic research institutions in the natural and exact sciences.
Curesponse is on a mission to improve cancer treatment. Today patients are routinely prescribed drugs which don’t work leading to enormous frustration and confusion. Curesponse’s cutting edge functional platform will match the correct drug to the patients cancer, improving survival and saving unnecessary medical interventions.
Curesponse’s technology represents the next step in personalized cancer medicine, moving prediction capabilities beyond genomics and into the world of functional response on living patient cells.
Mr. Guy Neev
Co-Founder & CEO
Mr. Neev has more than 20 years of experience in executive level positions in the medical and high tech industries. He served as the Chief Executive Officer of Check-Cap Ltd (NASDAQ:CHEK) and Cappella (Now: Arravasc ). During his time at Check-Cap he led the Company from inception, through its successful initial public offering in the United States and listing of its securities on Nasdaq.
Dr. Ravid Straussman
Dr. Ravid Straussman is a senior scientist leading a research group in the Department of Molecular Cell Biology at the Weizmann Institute of Science. Dr. Straussman completed a M.D./Ph.D. program at the Hebrew University medical school, Israel. Dr. Straussman is the author of numerous scientific publications in top-tier journals such as Science and Nature, and received multiple awards including the AACR scholar in training award (2012) and the Neufeld memorial research prize (2014).
Dr. Seth Salpeter
Co-Founder & CTO
Dr. Salpeter has deep experience in developing and bringing new biotechnologies to market. He previously served as Chief Scientist and VP Business Development at Sight Diagnostics and worked in pharmaceuticals as a Pharmaceutical analyst at Biotechnology General (Ferring). Dr. Salpeter holds a Ph.D in biochemistry from the Hebrew University and performed Post-Doctoral studies at the Institute for Drug Research, the Hebrew University School of Pharmacy.
Dr. Vered Bar
Vice President Research & Development
Dr. Bar has an experience in managing R&D projects in the pharmaceutical industry. She previously worked at Regenera Pharma and executed its pre-clinical studies, and served as the chief scientific advisor of Forum-MD. Dr Bar holds a Ph.D in life sciences from the Weizmann institute.
Dr. Yair Schindel
Managing partner and co-founder of aMoon. A successful executive, investor, board or advisory board member in several healthcare startups. Founding CEO of the State of Israel’s National Digital Bureau and of the MAOZ Network, an NGO building collaboration between Israel’s most influential leaders.